PSMA ligands for PET imaging of prostate cancer

Sarah M. Schwarzenboeck, Isabel Rauscher, Christina Bluemel, Wolfgang P. Fendler, Steven Rowe, Martin Gilbert Pomper, Ali Asfhar-Oromieh, Ken Herrmann, Matthias Eiber

Research output: Contribution to journalArticle

Abstract

Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared with standard-of-care imaging. For high-risk primary prostate cancer, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases. For both clinical indications in recurrent as well as in primary prostate cancer, preliminary data demonstrate a substantial impact on clinical management. Emerging data imply that intraprostatic tumor localization, therapy stratification, and treatment monitoring of advanced disease in specific clinical situations might become future indications. Current criteria for image reporting of PSMA ligand PET are evolving given the expanding body of literature on physiologic and pathologic uptake patterns and pitfalls. This article intends to give an educational overview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretation, clinical indications, diagnostic potential, and impact on treatment planning.

Original languageEnglish (US)
Pages (from-to)1545-1552
Number of pages8
JournalJournal of Nuclear Medicine
Volume58
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Prostatic Neoplasms
Ligands
Standard of Care
Retrospective Studies
Neoplasm Metastasis
Bone and Bones
human glutamate carboxypeptidase II
Neoplasms
Therapeutics

Keywords

  • PET/CT
  • Prostate cancer
  • PSMA

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Schwarzenboeck, S. M., Rauscher, I., Bluemel, C., Fendler, W. P., Rowe, S., Pomper, M. G., ... Eiber, M. (2017). PSMA ligands for PET imaging of prostate cancer. Journal of Nuclear Medicine, 58(10), 1545-1552. https://doi.org/10.2967/jnumed.117.191031

PSMA ligands for PET imaging of prostate cancer. / Schwarzenboeck, Sarah M.; Rauscher, Isabel; Bluemel, Christina; Fendler, Wolfgang P.; Rowe, Steven; Pomper, Martin Gilbert; Asfhar-Oromieh, Ali; Herrmann, Ken; Eiber, Matthias.

In: Journal of Nuclear Medicine, Vol. 58, No. 10, 01.10.2017, p. 1545-1552.

Research output: Contribution to journalArticle

Schwarzenboeck, SM, Rauscher, I, Bluemel, C, Fendler, WP, Rowe, S, Pomper, MG, Asfhar-Oromieh, A, Herrmann, K & Eiber, M 2017, 'PSMA ligands for PET imaging of prostate cancer', Journal of Nuclear Medicine, vol. 58, no. 10, pp. 1545-1552. https://doi.org/10.2967/jnumed.117.191031
Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe S, Pomper MG et al. PSMA ligands for PET imaging of prostate cancer. Journal of Nuclear Medicine. 2017 Oct 1;58(10):1545-1552. https://doi.org/10.2967/jnumed.117.191031
Schwarzenboeck, Sarah M. ; Rauscher, Isabel ; Bluemel, Christina ; Fendler, Wolfgang P. ; Rowe, Steven ; Pomper, Martin Gilbert ; Asfhar-Oromieh, Ali ; Herrmann, Ken ; Eiber, Matthias. / PSMA ligands for PET imaging of prostate cancer. In: Journal of Nuclear Medicine. 2017 ; Vol. 58, No. 10. pp. 1545-1552.
@article{a522355be9144215b5c8514a1cd62881,
title = "PSMA ligands for PET imaging of prostate cancer",
abstract = "Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared with standard-of-care imaging. For high-risk primary prostate cancer, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases. For both clinical indications in recurrent as well as in primary prostate cancer, preliminary data demonstrate a substantial impact on clinical management. Emerging data imply that intraprostatic tumor localization, therapy stratification, and treatment monitoring of advanced disease in specific clinical situations might become future indications. Current criteria for image reporting of PSMA ligand PET are evolving given the expanding body of literature on physiologic and pathologic uptake patterns and pitfalls. This article intends to give an educational overview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretation, clinical indications, diagnostic potential, and impact on treatment planning.",
keywords = "PET/CT, Prostate cancer, PSMA",
author = "Schwarzenboeck, {Sarah M.} and Isabel Rauscher and Christina Bluemel and Fendler, {Wolfgang P.} and Steven Rowe and Pomper, {Martin Gilbert} and Ali Asfhar-Oromieh and Ken Herrmann and Matthias Eiber",
year = "2017",
month = "10",
day = "1",
doi = "10.2967/jnumed.117.191031",
language = "English (US)",
volume = "58",
pages = "1545--1552",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

TY - JOUR

T1 - PSMA ligands for PET imaging of prostate cancer

AU - Schwarzenboeck, Sarah M.

AU - Rauscher, Isabel

AU - Bluemel, Christina

AU - Fendler, Wolfgang P.

AU - Rowe, Steven

AU - Pomper, Martin Gilbert

AU - Asfhar-Oromieh, Ali

AU - Herrmann, Ken

AU - Eiber, Matthias

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared with standard-of-care imaging. For high-risk primary prostate cancer, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases. For both clinical indications in recurrent as well as in primary prostate cancer, preliminary data demonstrate a substantial impact on clinical management. Emerging data imply that intraprostatic tumor localization, therapy stratification, and treatment monitoring of advanced disease in specific clinical situations might become future indications. Current criteria for image reporting of PSMA ligand PET are evolving given the expanding body of literature on physiologic and pathologic uptake patterns and pitfalls. This article intends to give an educational overview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretation, clinical indications, diagnostic potential, and impact on treatment planning.

AB - Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared with standard-of-care imaging. For high-risk primary prostate cancer, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases. For both clinical indications in recurrent as well as in primary prostate cancer, preliminary data demonstrate a substantial impact on clinical management. Emerging data imply that intraprostatic tumor localization, therapy stratification, and treatment monitoring of advanced disease in specific clinical situations might become future indications. Current criteria for image reporting of PSMA ligand PET are evolving given the expanding body of literature on physiologic and pathologic uptake patterns and pitfalls. This article intends to give an educational overview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretation, clinical indications, diagnostic potential, and impact on treatment planning.

KW - PET/CT

KW - Prostate cancer

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=85030867019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030867019&partnerID=8YFLogxK

U2 - 10.2967/jnumed.117.191031

DO - 10.2967/jnumed.117.191031

M3 - Article

VL - 58

SP - 1545

EP - 1552

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -